1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Plexiform Neurofibroma: new trials by email Literature Review of Plexiform Neurofibroma trials Research Report on Plexiform Neurofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 177 | 2026-03-31 | 2026-05-27 |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 3 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 167 | 2023-06-20 | 2025-03-06 |
Neurofibroma, Plexiform (2) · Neurofibromatosis 1 (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Nerve Tissue (2) · Nerve Sheath Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Neurofibroma (2) · Neuromuscular Diseases (2) · Peripheral Nervous System Diseases (2) · Peripheral Nervous System Neoplasms (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Neoplastic Syndromes, Hereditary (1) · Neurocutaneous Syndromes (1)
Control Groups (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1)
China (2)
Wenbin Li, MD (1)